Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
143 hedge funds and large institutions have $779M invested in Infinity Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 42 increasing their positions, 38 reducing their positions, and 13 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
208% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 13
29% more capital invested
Capital invested by funds: $606M → $779M (+$173M)
21% more funds holding
Funds holding: 118 → 143 (+25)
11% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 38
1.69% more ownership
Funds ownership: 92.62% → 94.31% (+1.7%)
51% less call options, than puts
Call options by funds: $9.58M | Put options by funds: $19.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.1M |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$8.48M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$6.06M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$6.01M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$5.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$22.8M |
| 2 |
HM
HealthCor Management
New York
|
-$13.7M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.92M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.55M |
| 5 |
BC
Broadfin Capital
New York
|
-$5.89M |
INFI Hedge Fund Activity: Q4 2014 in Review
143 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q4 2014, worth a combined $779M — up 29% from $606M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new INFI positions and 13 closed out — a net gain of 27 holders — while 42 added to existing stakes and 38 trimmed.
The largest buyer was Vanguard Group, adding an estimated $11.1M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $22.8M sold.
- 143 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q4 2014, up from 118 in Q3 2014.
- Funds reported $779M of Infinity Pharmaceuticals, Inc. stock for Q4 2014, up 29% quarter-over-quarter.
- 40 funds opened new Infinity Pharmaceuticals, Inc. positions in Q4 2014 and 13 closed out, a net change of +27 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q4 2014 was Vanguard Group, an estimated $11.1M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q4 2014 was Point72 Asset Management, an estimated $22.8M sold.
Based on aggregated 13F filings for Q4 2014.